The global veterinary regenerative medicine market accounted for USD 0.289 billion in 2023 and is expected to reach at USD 1.06 billion by 2034 with a CAGR of 12.55% during the forecast period 2024-2034. Surge in spending on pets, increase in research & development in regenerative medicine, rising prevalence of both acute & chronic diseases among pets, surge in pet adoptions, growing prevalence of orthopedic diseases, such as osteoarthritis & soft tissue injuries in companion animals, increasing initiatives by public & private organizations, and rising introduction of innovative veterinary regenerative medicine are some of the key factors boosting the market growth.
Rising introduction of innovative veterinary regenerative medicine is predicted to boost the market growth during the forecast period. Veterinary regenerative medicine utilizes advanced methods to assist in the regeneration of injured tissues and organs in animals. This field employs stem cells, growth factors, and various biomaterials to encourage the development of new tissues and enhance the body's innate healing mechanisms. For instance, in August 2023, VetStem, Inc., is revolutionizing the delivery of platelet-rich plasma to patients through the introduction of their latest off-the-shelf PRP product. Known as PrecisePRP™, this leucoreduced, allogeneic, pooled, freeze-dried PRP aims to offer a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses.
By product, stem cells was the highest revenue-grossing segment in the global veterinary regenerative medicine market in 2023 owing to the expanding range of stem cell-based therapy choices for dogs, cats, & horses, and rise in the introduction of innovative treatments. For instance, in April 2022, Boehringer Ingelheim introduced RenuTend, a stem cell therapy designed for horses to facilitate the recovery from tendon and suspensory ligament injuries. Additionally, others is anticipated to grow at the fastest CAGR during the forecast period. This includes products such as PRP, which are growingly utilized as treatment options in regenerative medicine for animal health.
By animal type, small animals was the highest revenue-grossing segment in the global veterinary regenerative medicine market in 2023 owing to the increasing pet population, with pets being increasingly treated as family members, chronic diseases are becoming more common among pets, leading to higher expenses for their care, and rising investment by major market players. For instance, in January 2024, Gallant Therapeutics has declared the successful closure of its series A financing round, raising more than $15 million to progress its lineup of "off-the-shelf" stem cell therapies for pets. Additionally, large animals is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of products for treating injuries and orthopedic disorders in horses.
By application, orthopedics was the highest revenue-grossing segment in the global veterinary regenerative medicine market in 2023 owing to the rising utilization of regenerative medicine therapy for treating orthopedic diseases, expanding applications of stem cells & PRP, and increasing clinical evidence. Additionally, others is predicted to grow at the fastest CAGR during the forecast period owing to the growing research & development activities for the development of novel treatments and surge in collaborations among market players. For instance, in October 2023, Athersys, Inc., specializing in cell therapy and regenerative medicine, focusing on MultiStem for critical care purposes, and Multipotent Adult Progenitor Cell (MAPC) technology for veterinary applications in horses, dogs, and cats, has entered into a licensing deal with Ardent Animal Health (Ardent). Ardent is a privately owned veterinary biotech company dedicated to developing regenerative medicine and cancer treatments for animals.
By end-user, veterinary hospitals & clinics was the highest revenue-grossing segment in the global veterinary regenerative medicine market in 2023 owing to the significant presence of veterinary clinics & hospitals, high volume of patient visits, increasing concerns about pet health, and increase in the number of clinical trial procedures. For instance, in November 2023, A trial has been initiated to evaluate chimeric antigen receptor (CAR) T-cell therapy in dogs, utilizing modified white blood cells and the body's immune system to combat cancer. Additionally, veterinary research institutes is predicted to grow at the fastest CAGR during the forecast period owing to surge in research & development efforts in regenerative medicine for animal health, and growing body of clinical evidence.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising recognition of the advantages of regenerative therapy, presence of prominent companies in the field, increase in initiatives by market players, and expanding research & development efforts. For instance, in December 2023, Zoetis Inc. recently concluded a study examining alpha-2-macroglobulin (A2M) and other notable proteins found in regenerative medicine tools used to treat equine osteoarthritis (OA), such as Pro-Stride APS, Restigen PRP, and Alpha2EQ devices. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of facilities providing regenerative medicine services, increasing pet population, higher spending on animals, ongoing development in veterinary healthcare infrastructure, and increased investment from key market players. For instance, in May 2023, StemCures, headquartered in the United States, revealed a substantial investment of $54 million to build India's largest stem cell manufacturing facility in Hyderabad.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Rising introduction of innovative veterinary regenerative medicine is predicted to boost the market growth during the forecast period. Veterinary regenerative medicine utilizes advanced methods to assist in the regeneration of injured tissues and organs in animals. This field employs stem cells, growth factors, and various biomaterials to encourage the development of new tissues and enhance the body's innate healing mechanisms. For instance, in August 2023, VetStem, Inc., is revolutionizing the delivery of platelet-rich plasma to patients through the introduction of their latest off-the-shelf PRP product. Known as PrecisePRP™, this leucoreduced, allogeneic, pooled, freeze-dried PRP aims to offer a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses.
By product, stem cells was the highest revenue-grossing segment in the global veterinary regenerative medicine market in 2023 owing to the expanding range of stem cell-based therapy choices for dogs, cats, & horses, and rise in the introduction of innovative treatments. For instance, in April 2022, Boehringer Ingelheim introduced RenuTend, a stem cell therapy designed for horses to facilitate the recovery from tendon and suspensory ligament injuries. Additionally, others is anticipated to grow at the fastest CAGR during the forecast period. This includes products such as PRP, which are growingly utilized as treatment options in regenerative medicine for animal health.
By animal type, small animals was the highest revenue-grossing segment in the global veterinary regenerative medicine market in 2023 owing to the increasing pet population, with pets being increasingly treated as family members, chronic diseases are becoming more common among pets, leading to higher expenses for their care, and rising investment by major market players. For instance, in January 2024, Gallant Therapeutics has declared the successful closure of its series A financing round, raising more than $15 million to progress its lineup of "off-the-shelf" stem cell therapies for pets. Additionally, large animals is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of products for treating injuries and orthopedic disorders in horses.
By application, orthopedics was the highest revenue-grossing segment in the global veterinary regenerative medicine market in 2023 owing to the rising utilization of regenerative medicine therapy for treating orthopedic diseases, expanding applications of stem cells & PRP, and increasing clinical evidence. Additionally, others is predicted to grow at the fastest CAGR during the forecast period owing to the growing research & development activities for the development of novel treatments and surge in collaborations among market players. For instance, in October 2023, Athersys, Inc., specializing in cell therapy and regenerative medicine, focusing on MultiStem for critical care purposes, and Multipotent Adult Progenitor Cell (MAPC) technology for veterinary applications in horses, dogs, and cats, has entered into a licensing deal with Ardent Animal Health (Ardent). Ardent is a privately owned veterinary biotech company dedicated to developing regenerative medicine and cancer treatments for animals.
By end-user, veterinary hospitals & clinics was the highest revenue-grossing segment in the global veterinary regenerative medicine market in 2023 owing to the significant presence of veterinary clinics & hospitals, high volume of patient visits, increasing concerns about pet health, and increase in the number of clinical trial procedures. For instance, in November 2023, A trial has been initiated to evaluate chimeric antigen receptor (CAR) T-cell therapy in dogs, utilizing modified white blood cells and the body's immune system to combat cancer. Additionally, veterinary research institutes is predicted to grow at the fastest CAGR during the forecast period owing to surge in research & development efforts in regenerative medicine for animal health, and growing body of clinical evidence.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising recognition of the advantages of regenerative therapy, presence of prominent companies in the field, increase in initiatives by market players, and expanding research & development efforts. For instance, in December 2023, Zoetis Inc. recently concluded a study examining alpha-2-macroglobulin (A2M) and other notable proteins found in regenerative medicine tools used to treat equine osteoarthritis (OA), such as Pro-Stride APS, Restigen PRP, and Alpha2EQ devices. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of facilities providing regenerative medicine services, increasing pet population, higher spending on animals, ongoing development in veterinary healthcare infrastructure, and increased investment from key market players. For instance, in May 2023, StemCures, headquartered in the United States, revealed a substantial investment of $54 million to build India's largest stem cell manufacturing facility in Hyderabad.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Animal Type, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Veterinary Regenerative Medicine Market Report 2023 - 2034
Veterinary Regenerative Medicine Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Stem Cells
- Others
Veterinary Regenerative Medicine Market Analysis & Forecast by Animal Type 2023 - 2034 (Revenue USD Bn)
- Large Animals
- Small Animals
Veterinary Regenerative Medicine Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Trauma/Wound Care
- Orthopedics
- Others
Veterinary Regenerative Medicine Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Veterinary Research Institutes
- Veterinary Hospitals/Clinics
Veterinary Regenerative Medicine Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Veterinary Regenerative Medicine Market: Product Estimates & Trend Analysis
8. Veterinary Regenerative Medicine Market: Animal Type Estimates & Trend Analysis
9. Veterinary Regenerative Medicine Market: Application Estimates & Trend Analysis
10. Veterinary Regenerative Medicine Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Veterinary Regenerative Medicine Market
13. Europe Global Veterinary Regenerative Medicine Market
14. Asia Pacific Global Veterinary Regenerative Medicine Market
15. Latin America Global Veterinary Regenerative Medicine Market
16. MEA Global Veterinary Regenerative Medicine Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Zoetis
- Ardent
- Dechra
- Vetherapy
- Vetbiologics
- VetStem Inc.
- Enso Discoveries
- Animal Cell Therapies Inc.
- ACell Inc. (Integra LifeSciences)
- Boehringer Ingelheim International GmbH
